[go: up one dir, main page]

PE20190355A1 - Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo - Google Patents

Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo

Info

Publication number
PE20190355A1
PE20190355A1 PE2018003336A PE2018003336A PE20190355A1 PE 20190355 A1 PE20190355 A1 PE 20190355A1 PE 2018003336 A PE2018003336 A PE 2018003336A PE 2018003336 A PE2018003336 A PE 2018003336A PE 20190355 A1 PE20190355 A1 PE 20190355A1
Authority
PE
Peru
Prior art keywords
cysteine
glutamic acid
peptide
acid
same
Prior art date
Application number
PE2018003336A
Other languages
English (en)
Inventor
Jung Kuk Kim
Young Jin Park
In Young Choi
Sung Youb Jung
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60787387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190355(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of PE20190355A1 publication Critical patent/PE20190355A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se refiere a un derivado de glucagon o un conjugado que contiene el mismo, y en forma especifica, una composicion farmaceutica, que comprende un peptido que comprende la secuencia de aminoacidos de la siguiente formula general 1: X1-X2-QGTF-X7-SD-X10-S-X12-X13-X14-X15-X16-X17-X18-X19-X20-X21-X23-X24-W-L-X27-X28-X29-X30 (Formula general 1, SEQ ID NO: 45), en donde X1 es histidina (H), desamino-histidilo, N-dimetil-histidilo, beta-hidroxiimidazopropionilo, 4-imidazoacetilo, entre otros; X2 es acido alfa-metil-glutamico, acido aminoisobutirico (Aib), D-alanina, glicina (G), entre otros; X7 es treonina (T), valina (V), o cisteina (C); X10 es tirosina (Y) o cisteina (C ); X12 es lisina (K) o cisteina (C ); X13 es tirosina (Y) o cisteina (C ); X14 es leucina (L) o cisteina (C ); X15 es acido aspartico (D), acido glutamico (E), o cisteina (C); X16 es acido glutamico (E ) acido aspartico (D), serina (S), acido alfa-metil-glutamico, o cisteina (C), o esta ausente; X17 es acido aspartico (D), glutamina (Q), acido glutamico (E ), entre otros; X18 es alanina (A), acido aspartico (D), acido glutamico (E ), entre otros; X19 es alanina (A), arginina (R ), entre otros; X20 es lisina (K), histidina (H), entre otros; X21 es acido aspartico (D), acido glutamico (E ); entre otros; X23 es isoleucina (I), valina (V), entre otros; X24 es valina (V), arginina (R ), entre otros, X27 es isoleucina (I), valina (V), entre otros; X28 es glutamina (Q), lisina (K); X29 es lisina (K), alanina ( A); X30 es cisteina (C); entre otros; donde el extremo C-terminal del peptido esta amidado, no modificado y el peptido es un derivado del glucagon nativo capaz de activar un receptor de glucagon, el cual comprende una secuencia de aminoacidos que consiste en las SEQ ID NOS: 2 a 44. Tambien se refiere a un conjugado aislado que comprende un resto peptidico y un resto de material biocompatible que se liga al resto del peptido. Dicha composicion farmaceutica es util para prevenir o tratar hipoglucemia, sindrome metabolico e hiperinsulinismo congenito.
PE2018003336A 2016-06-29 2017-06-29 Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo PE20190355A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160081995 2016-06-29
KR20160182982 2016-12-29
KR20170069217 2017-06-02

Publications (1)

Publication Number Publication Date
PE20190355A1 true PE20190355A1 (es) 2019-03-07

Family

ID=60787387

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003336A PE20190355A1 (es) 2016-06-29 2017-06-29 Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo

Country Status (23)

Country Link
US (1) US11142559B2 (es)
EP (1) EP3479841A4 (es)
JP (2) JP7208020B2 (es)
KR (2) KR102005457B1 (es)
CN (1) CN109641035A (es)
AU (1) AU2017289014B2 (es)
BR (1) BR112018077457A2 (es)
CA (1) CA3029518A1 (es)
CL (1) CL2018003754A1 (es)
CO (1) CO2019003182A2 (es)
DO (1) DOP2018000297A (es)
EC (1) ECSP19021223A (es)
IL (1) IL263934B2 (es)
MX (1) MX2019000019A (es)
MY (1) MY190855A (es)
PE (1) PE20190355A1 (es)
PH (1) PH12018502742A1 (es)
SG (1) SG11201811697SA (es)
TN (1) TN2018000452A1 (es)
TW (1) TWI757305B (es)
UA (1) UA126662C2 (es)
WO (1) WO2018004283A2 (es)
ZA (1) ZA201900470B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
MX387560B (es) * 2014-03-31 2025-03-18 Hanmi Pharmaceutical Co Ltd Procedimiento para mejorar la solubilidad de proteínas y péptidos usando un enlace del fragmento fc de inmunoglobulina.
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX2019007339A (es) 2016-12-29 2019-09-06 Hoffmann La Roche Compuestos de pirazolopirimidina y metodos de uso de los mismos.
US20200230250A1 (en) * 2017-02-03 2020-07-23 Hanmi Pharm. Co., Ltd. Long-acting conjugate of a physiologically active material and use thereof
CN113164559A (zh) * 2018-10-04 2021-07-23 韩美药品株式会社 胰高血糖素和包括胰高血糖素的组合产品的治疗用途
JP2022514835A (ja) * 2018-12-21 2022-02-16 ハンミ ファーマシューティカル カンパニー リミテッド インスリン及びグルカゴンを含む薬学組成物
CN110551203B (zh) * 2019-09-25 2023-02-10 成都奥达生物科技有限公司 一种艾塞那肽类似物
US20230000950A1 (en) * 2019-10-04 2023-01-05 Hanmi Pharm. Co., Ltd. Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same
CN110845601B (zh) * 2019-10-12 2021-01-19 广东药科大学 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
BR112022019518A2 (pt) * 2020-04-03 2023-02-07 Hanmi Pharm Ind Co Ltd Composição farmacêutica para prevenir ou tratar mucosite induzida por radioterapia, quimioterapia, ou uma combinação das mesmas, que compreende derivados de glp-2 ou um conjugado de atuação duradoura do mesmo
TW202203963A (zh) * 2020-04-20 2022-02-01 南韓商韓美藥品股份有限公司 用於預防或治療高血脂症之包含三重升糖素／ｇｌｐ－１／ｇｉｐ受體促效劑或其接合物之組成物及其使用方法
CN115515641B (zh) * 2020-04-29 2025-11-18 株式会社原真生物技术 新型蛋白质结合物及其非酒精性脂肪性肝炎、肥胖及糖尿病的预防或治疗用途
MX2022014669A (es) * 2020-05-22 2023-02-13 Hanmi Pharm Ind Co Ltd Formulacion liquida de conjugado de derivado de glucagon de accion prolongada.
IL298428A (en) * 2020-05-22 2023-01-01 Hanmi Pharm Ind Co Ltd Liquid formulation
EP4181881A1 (en) 2020-07-14 2023-05-24 Universität Heidelberg Oral pharmaceutical compositions comprising lipid conjugates
BR112023000515A2 (pt) * 2020-07-15 2023-03-21 Hanmi Pharm Ind Co Ltd Composição farmacêutica e seu uso
IL305549A (en) * 2021-04-09 2023-10-01 Hanmi Pharm Ind Co Ltd Pharmaceutical composition for the prevention or treatment of chronic kidney disease including a glucagon derivative
KR20230095666A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 간 표적 물질 및 이의 용도

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408037A (en) 1991-01-17 1995-04-18 Zymogenetics, Inc. Methods for detecting glucagon antagonists
GB9423277D0 (en) 1994-11-18 1995-01-11 Univ Nottingham Pulsed laser deposition of coatings
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
DE19618812C1 (de) 1996-05-10 1997-11-20 Karlsruhe Forschzent Sensor zum Nachweis von Proteinen und Verfahren zu dessen Herstellung
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
EP2275117B1 (en) 2001-07-31 2016-10-26 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services GLP-1, exendin-4, peptide analogs and uses thereof
HRP20050683A2 (en) 2003-03-19 2006-07-31 Eli Lilly And Company Polyethylene glycol linked glp-1 compounds
RU2352583C2 (ru) 2003-11-13 2009-04-20 Ханми Фарм. Инд. Ко., Лтд. ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ Fc-ОБЛАСТЬ ИММУНОГЛОБУЛИНА В КАЧЕСТВЕ НОСИТЕЛЯ
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
WO2007124461A2 (en) 2006-04-20 2007-11-01 Amgen Inc. Glp-1 compounds
US20090098130A1 (en) 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
JP2008169195A (ja) 2007-01-05 2008-07-24 Hanmi Pharmaceutical Co Ltd キャリア物質を用いたインスリン分泌ペプチド薬物結合体
WO2008086086A2 (en) 2007-01-05 2008-07-17 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
EP2158214B1 (en) * 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
KR20100049032A (ko) 2007-06-19 2010-05-11 오츠카 가가쿠 가부시키가이샤 당사슬 부가 ｇｌｐ―１ 펩티드
CN101868476B (zh) 2007-09-05 2015-02-25 诺沃-诺迪斯克有限公司 胰高血糖素样肽-1衍生物及其制药用途
CN101983066B (zh) 2008-01-30 2016-06-29 印第安那大学科技研究公司 基于酯的胰岛素前药
KR20110039230A (ko) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 생리학적 ｐＨ 완충액에서 강화된 용해도 및 안정성을 나타내는 글루카곤 유사체
PA8830501A1 (es) * 2008-06-17 2010-07-27 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
BRPI0915282A2 (pt) * 2008-06-17 2017-02-07 Univ Indiana Res & Tech Corp agonistas mistos baseados no gip para o tratamento de distúrbios metabólicos e obesidade
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
PE20120914A1 (es) 2009-06-16 2012-08-22 Univ Indiana Res & Tech Corp Compuestos glucagon activo de receptor de gip
DK2454282T3 (en) 2009-07-13 2015-05-04 Zealand Pharma As acetylated glucagonanaloger
GB0917072D0 (en) 2009-09-29 2009-11-11 Univ Ulster Peptide analogues of glucagon for diabetes therapy
US8703701B2 (en) * 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
MX342409B (es) 2010-01-20 2016-09-28 Zealand Pharma As Tratamiento de enfermedades cardiacas.
CN102918055B (zh) * 2010-03-26 2017-03-29 诺沃—诺迪斯克有限公司 新的胰高血糖素类似物
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp GLUCAGON SUPERFAMILY PEPTIDES WITH G-PROTEIN-COUPLED RECEPTOR ACTIVITY
KR101382593B1 (ko) * 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
KR20130132931A (ko) 2010-12-22 2013-12-05 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Gip 수용체 활성을 나타내는 글루카곤 유사체들
WO2012150503A2 (en) 2011-05-03 2012-11-08 Zealand Pharma A/S Glu-glp-1 dual agonist signaling-selective compounds
AU2012255119B2 (en) * 2011-05-18 2017-04-20 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
DK3878859T5 (da) * 2011-06-10 2024-06-10 Hanmi Science Co Ltd Hidtil ukendte oxyntomodulinderivater og farmaceutisk præparat til behandling af fedme omfattende disse
SI2721062T1 (sl) 2011-06-17 2019-03-29 Hanmi Science Co., Ltd. Konjugat, obsegajoč oksintomodulinski in imunoglobinski fragment, in uporaba le-tega
WO2013004983A1 (en) * 2011-07-04 2013-01-10 Imperial Innovations Limited Novel compounds and their effects on feeding behaviour
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
WO2013120022A2 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
CN112142855A (zh) 2012-05-18 2020-12-29 爱德迪安（北京）生物技术有限公司 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
CA2877127A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
ES2602486T3 (es) 2012-06-21 2017-02-21 Indiana University Research And Technology Corporation Análogos de glucagón que muestran actividad de receptor de GIP
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
AR094821A1 (es) 2012-07-25 2015-09-02 Hanmi Pharm Ind Co Ltd Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
KR101993393B1 (ko) * 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
MY168536A (en) * 2012-11-06 2018-11-12 Hanmi Pharm Ind Co Ltd Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin fc region
AU2013347975B2 (en) * 2012-11-20 2018-07-26 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
CA2891929C (en) * 2012-11-20 2022-07-19 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals
MX2015008114A (es) 2012-12-21 2015-11-06 Sanofi Sa Derivados de exendina-4.
SI2986313T1 (sl) 2013-04-18 2019-09-30 Novo Nordisk A/S Stabilni koagonisti GLP-1 / glukagonskega receptorja z dolgotrajnim učinkom za medicinsko uporabo
EP3033355A1 (en) 2013-08-16 2016-06-22 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
AR100639A1 (es) * 2014-05-29 2016-10-19 Hanmi Pharm Ind Co Ltd Composición para tratar diabetes que comprende conjugados de análogos de insulina de acción prolongada y conjugados de péptidos insulinotrópicos de acción prolongada
TWI684458B (zh) 2014-05-30 2020-02-11 南韓商韓美藥品股份有限公司 包含胰島素及ｇｌｐ-１/昇糖素雙重促效劑之治療糖尿病之組成物
TWI802396B (zh) * 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
WO2016049190A1 (en) 2014-09-24 2016-03-31 Indiana University Research And Technology Corporation Incretin-insulin conjugates
KR102291020B1 (ko) 2014-12-30 2021-08-20 한미약품 주식회사 안정성이 증가된 글루카곤 유도체
DK3322437T5 (da) * 2015-06-30 2024-10-07 Hanmi Pharmaceutical Co Ltd Glukagonderivat og en sammensætning omfattende et langtidsvirkende konjugat af samme
TW201718629A (zh) 2015-09-25 2017-06-01 韓美藥品股份有限公司 包含多個生理多肽及免疫球蛋白Ｆｃ區之蛋白質接合物
JP6989503B2 (ja) 2015-12-02 2022-01-05 ハンミ ファーマシューティカル カンパニー リミテッド 脂肪酸誘導体を用いたタンパク質結合体及びその製造方法
PE20250556A1 (es) 2015-12-31 2025-02-24 Hanmi Pharmaceutical Co Ltd Agonista triple de receptores de glucagon/glp-1/gip

Also Published As

Publication number Publication date
KR20180002544A (ko) 2018-01-08
AU2017289014A1 (en) 2019-02-14
KR20190092344A (ko) 2019-08-07
ZA201900470B (en) 2020-07-29
JP7208020B2 (ja) 2023-01-18
EP3479841A2 (en) 2019-05-08
IL263934A (en) 2019-02-03
AU2017289014B2 (en) 2019-12-05
TWI757305B (zh) 2022-03-11
KR102005457B1 (ko) 2019-07-30
JP7399212B2 (ja) 2023-12-15
JP2022107595A (ja) 2022-07-22
KR102395856B1 (ko) 2022-05-10
BR112018077457A2 (pt) 2019-04-02
CA3029518A1 (en) 2018-01-04
WO2018004283A3 (ko) 2018-02-22
TW201803894A (zh) 2018-02-01
US20190119347A1 (en) 2019-04-25
CL2018003754A1 (es) 2019-02-08
JP2019524675A (ja) 2019-09-05
NZ750267A (en) 2023-12-22
IL263934B1 (en) 2023-06-01
IL263934B2 (en) 2023-10-01
TN2018000452A1 (en) 2020-06-15
ECSP19021223A (es) 2019-04-30
CN109641035A (zh) 2019-04-16
SG11201811697SA (en) 2019-01-30
PH12018502742A1 (en) 2019-04-15
EP3479841A4 (en) 2020-03-04
MY190855A (en) 2022-05-12
UA126662C2 (uk) 2023-01-11
US11142559B2 (en) 2021-10-12
MX2019000019A (es) 2019-05-06
WO2018004283A2 (ko) 2018-01-04
CO2019003182A2 (es) 2019-06-11
DOP2018000297A (es) 2019-03-15

Similar Documents

Publication Publication Date Title
PE20190355A1 (es) Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo
PE20140765A1 (es) Derivados de oxintomodulina novedosos y composicion farmaceutica para tratar la obesidad que comprende los mismos
PE20171154A1 (es) Derivados de glucagon con estabilidad mejorada
PE20120358A1 (es) Mutantes fgf21 y usos de los mismos
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
PE20211300A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
PE20171442A1 (es) Peptidos y combinacion de peptidos novedosos para su uso en inmunoterapia contra diversos tumores
PE20120563A1 (es) Construcciones novedosas de proteina del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv
IL262805B2 (en) Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
JP2018504901A5 (es)
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
AR094181A1 (es) Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon
AR105616A1 (es) Proteínas de fusión
IL276170B2 (en) Lipid-modified relaxin B peptide chains and their medical use
RU2020117156A (ru) Конъюгаты анти-cd40 антитела и лекарственного средства
PE20211417A1 (es) Analogos novedosos de glp-1
RU2015101697A (ru) Аналоги глюкагона, обладающие активностью рецептора gip
EA201291234A1 (ru) Аналоги глюкагона
PE20171058A1 (es) Composiciones y metodos de uso para tratar trastornos metabolicos
PE20140724A1 (es) Coagonistas del receptor de glucagon/glp-1
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
CL2012001686A1 (es) Analogo peptidico de oxintomodulina, en donde el aminoacido c-terminal es opcionalmente amidado; composicion farmaceutica que lo comprende y su uso en la preparacion de un medicamento para el tratamiento de diabetes no insulinodependiente u obesidad.
IL276294B1 (en) Human cd30 ligand antigen binding proteins
JP2016510728A5 (es)